Merck & Co. Inc. has added indifferent efficacy data to the safety signal seen in the top-line results of the phase IIb/III trial of its trispecific antibody remigromig in the treatment of diabetic macular edema (DME).The full data from the Brunello study, presented at the American Academy of Ophthalmology meeting on Oct. 10, show remigromig met the primary endpoint of noninferiority in mean change from baseline in best corrected visual acuity, compared to the active control arm treated with the anti-VEGF therapy Lucentis (ranibizumab, Roche Holding AG).
Geo Focus
Coverage Attributes:
Beta
Informative:
60
%
Data Driven:
28
%
Opinion:
3
%
Promotional:
3
%
Interviews Q&as:
2
%
Themes Covered:
Not enough data
Pitching Insights
Nuala Moran's coverage is heavily focused on the healthcare and pharmaceutical industry, with an emphasis on gene therapy, cancer research, and biopharmaceuticals. She also covers a significant amount of content related to regulatory matters in the European healthcare system.
Given Nuala's focus on scientific and healthcare topics, she would be most responsive to pitches that offer expert insights from researchers or professionals within the pharmaceutical industry who can provide valuable perspectives on gene therapy advancements, cancer research developments, or regulatory challenges within the European healthcare context.
Additionally, given her coverage of government announcements and legal policy regulations in the healthcare sector, sources with expertise in these areas may find success when reaching out to Nuala for potential collaboration.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Journalists With Similar Coverage:
Based on similarity of content.
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
